The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Identifying clinically relevant prognostic subgroups in node-positive postmenopausal HR+ early breast cancer patients treated with endocrine therapy: A combined analysis of 2,485 patients from ABCSG-8 and ATAC using the PAM50 risk of recurrence (ROR) score and intrinsic subtype.
Michael Gnant
Consultant or Advisory Role - Novartis
Honoraria - AstraZeneca; Novartis
Research Funding - AstraZeneca; NanoString Technologies; Novartis
Mitchell Dowsett
Honoraria - AstraZeneca
Research Funding - AstraZeneca
Martin Filipits
Research Funding - Sividon Diagnostics
Elena Lopez-Knowles
No relevant relationships to disclose
Richard Greil
Consultant or Advisory Role - AstraZeneca
Honoraria - AstraZeneca
Research Funding - AstraZeneca
Marija Balic
No relevant relationships to disclose
John W Cowens
Employment or Leadership Position - NanoString Technologies
Stock Ownership - NanoString Technologies
Torsten O. Nielsen
Consultant or Advisory Role - Bioclassifier
Research Funding - NanoString Technologies
Carl Shaper
No relevant relationships to disclose
Ivana Sestak
No relevant relationships to disclose
Christian Fesl
No relevant relationships to disclose
Jack M. Cuzick
Honoraria - AstraZeneca
Research Funding - AstraZeneca